EWTX SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 4, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 26, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Edgewise Therapeutics Reports Third Quarter 2026 Financial Results and Provides Pipeline Updates

Nov 4, 2026

8-K

Edgewise Therapeutics Reports Q2 2026 Financial Results and Completion of Muscular Dystrophy Business Sale

Aug 6, 2026

8-K/A

Edgewise Therapeutics Completes Sale of Sevasemten Program to Servier

Jul 16, 2026

8-K

Edgewise Therapeutics Completes Sale of Sevasemten to Servier for Up to $2.65 Billion

Jul 13, 2026

8-K

Edgewise Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 5, 2026

8-K

Edgewise Therapeutics to Sell Sevasemten and Muscular Dystrophy Business to Servier for Up to $2.65 Billion

Jun 1, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Apr 2, 2025

424B5

21,818,182 Shares

Jan 19, 2024

424B3

Registration

Jan 19, 2024

424B5

Shares of our common stock having an aggregate offering price of up to $125,000,000.

Jun 16, 2023

424B5

11,627,907 Shares

Sep 14, 2022

424B5

Common Stock

Sep 13, 2022

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 7, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 3, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Nov 7, 2024

S-3ASR

Shares of our common stock having an aggregate offering price of up to $175,000,000.

May 10, 2024

S-8

Registration

May 9, 2024

S-3MEF

Registration

Jan 19, 2024

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

FMR LLC (Filed by)

Nov 5, 2026

Fox Jonathan C (Reporting)

Oct 2, 2026

4/A

Nofi Michael (Reporting)

Aug 17, 2026

4/A

Donovan Joanne M. (Reporting)

Aug 17, 2026

4/A

Russell Alan J (Reporting)

Aug 17, 2026

4/A

MOORE JOHN R (Reporting)

Aug 17, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

May 6, 2022

CORRESP

Form CORRESP - Correspondence

May 3, 2022

LETTER

Form UPLOAD - SEC-generated letter

Apr 8, 2022

EFFECT

Form EFFECT - Notice of Effectiveness

Mar 26, 2021

CORRESP

Form CORRESP - Correspondence

Mar 22, 2021

CORRESP

Form CORRESP - Correspondence

Mar 22, 2021

Edgewise Therapeutics, Inc. EWTX · SEC Filings